News LadRx Corporation

Equities

Market Closed - OTC Markets Other stock markets 07:21:13 26/06/2024 pm IST			5-day change	1st Jan Change
2.575 ^USD	+14.44%		+20.89%	+98.08%

04/06	LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License	CI
15/05	LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License	04/06	BU
LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License	04/06	CI
Investor Presentation: June 2024	04/06	PU
LadRx: Q1 Earnings Snapshot	15/05	AQ
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C Results in XOMA Making a $1 Million Milestone Payment to LadRx	12/01	AQ
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	12/01	DJ
LadRx Issues 2024 Update to Shareholders	09/01	BU
LadRx: Q3 Earnings Snapshot	14/11	AQ
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
LadRx : Modification to Rights of Security Holders - Form 8-K	11/23/11	PU
LadRx: Q2 Earnings Snapshot	14/23/14	AQ
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Investor Presentation: July 2023	15/23/15	PU
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation	22/23/22	BU
LadRx Announces Reverse Stock Split Effective as of May 17, 2023	18/23/18	BU
Reverse Split: 1 of 100	17/23/17	FA
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
LadRx Announces Reverse Stock Split	10/23/10	BU

No results for this search